Fibroblast Growth Factor 23

Produk Detail:
  • Author : Christian Faul
  • Publisher : Elsevier
  • Pages : 376 pages
  • ISBN : 0128180374
  • Rating : /5 from reviews
CLICK HERE TO GET THIS BOOK >>>Fibroblast Growth Factor 23

Download or Read online Fibroblast Growth Factor 23 full in PDF, ePub and kindle. this book written by Christian Faul and published by Elsevier which was released on 06 April 2021 with total page 376 pages. We cannot guarantee that Fibroblast Growth Factor 23 book is available in the library, click Get Book button and read full online book in your kindle, tablet, IPAD, PC or mobile whenever and wherever You Like. Fibroblast Growth Factor 23 describes how FGF23 was initially identified as a bone-derived factor targeting the kidney. As such, sections in this comprehensive book cover exciting research that shows that different FGF23 effects require distinct signaling receptors and mediators that differ among target tissues, cover FGF23 initially identified as a bone-derived factor targeting the kidney, look at FGF23 as a regulator of phosphate metabolism and beyond, and cover research on novel concepts of FGF receptor signaling. Additional sections cover biochemistry, pharmacology and nephrology, making this book an ideal reference source on FGF23. Provides a comprehensive collection of chapters on the diversity of FGF23's actions Highlights truly translational topics, from molecular signaling to physiology and mechanism of disease, discussing cell culture and animal models to study FGF23 Describes FGF23’s potential in the clinical setting as a biomarker or even drug target Presents leaders in the field who cover a wide spectrum of research backgrounds and expertise, including clinical and basic scientists who specialize in diseases, endocrinology, genetics, protein biochemistry, cell biology and physiology

Fibroblast Growth Factor 23

Fibroblast Growth Factor 23
  • Author : Christian Faul,Kenneth White,Orlando Gutierrez
  • Publisher : Elsevier
  • Release : 06 April 2021
GET THIS BOOK Fibroblast Growth Factor 23

Fibroblast Growth Factor 23 describes how FGF23 was initially identified as a bone-derived factor targeting the kidney. As such, sections in this comprehensive book cover exciting research that shows that different FGF23 effects require distinct signaling receptors and mediators that differ among target tissues, cover FGF23 initially identified as a bone-derived factor targeting the kidney, look at FGF23 as a regulator of phosphate metabolism and beyond, and cover research on novel concepts of FGF receptor signaling. Additional sections cover biochemistry, pharmacology

The Role of Circulating Fibroblast Growth Factor 23 FGF 23 in Chronic Kidney Disease Mineral Bone Disorder CKB MBD

The Role of Circulating Fibroblast Growth Factor 23  FGF 23  in Chronic Kidney Disease   Mineral Bone Disorder  CKB MBD
  • Author : Dr. Padmini Ajit Kumar Manghat,King's College London. Guy's, King's and St. Thomas's School of Medicine
  • Publisher : Unknown
  • Release : 16 June 2021
GET THIS BOOK The Role of Circulating Fibroblast Growth Factor 23 FGF 23 in Chronic Kidney Disease Mineral Bone Disorder CKB MBD

Background and aim: Fibroblast Growth Factor-23 (FGF-23) has been shown to be elevated in early stage CKD. The primary stimulus for this increase remains unclear and it is still unknown whether the increase in FGF-23 has a biological effect on bone metabolism and vascular calcification. The aim of the study was to investigate in a cross - sectional design (1) the factors which are associated with elevated serum FGF-23 (2) the association between FGF-23 and bone metabolism (3) the association between FGF-23 and

Fibroblast Growth Factor 23 in Canine Kidney Disease

Fibroblast Growth Factor 23 in Canine Kidney Disease
  • Author : Laura M. Harjes
  • Publisher : Unknown
  • Release : 16 June 2021
GET THIS BOOK Fibroblast Growth Factor 23 in Canine Kidney Disease

Chronic kidney disease (CKD) is associated with hyperphosphatemia, reduced vitamin D metabolite concentrations, and hyperparathyroidism. This syndrome is known as CKD-mineral and bone disorder (CKD-MBD). Recently it has been shown that increased fibroblast growth factor-23 (FGF23) concentration is one of the earliest biomarkers of CKD in people and cats. It is an independent risk factor for both progression of kidney disease and survival time in humans and cats. FGF23 information in healthy and CKD dogs is lacking. The primary objective

Fibroblast Growth Factor 23 as Novel Marker of Phosphate Homeostasis

Fibroblast Growth Factor 23 as Novel Marker of Phosphate Homeostasis
  • Author : Noreen Abbas,Aysha Habib Khan
  • Publisher : LAP Lambert Academic Publishing
  • Release : 10 December 2015
GET THIS BOOK Fibroblast Growth Factor 23 as Novel Marker of Phosphate Homeostasis

Fibroblast growth factor 23 (FGF-23), is recently discovered phosphaturic substance. It releases from bone osteocytes and plays a key role in the physiological regulation of phosphate metabolism. Excessive action of FGF23 results in several hypophosphatemic diseases characterized by impaired renal tubular phosphate reabsorption. In contrast, deficient action of FGF23 causes familial hyperphosphatemic tumoral calcinosis with enhanced renal tubular phosphate reabsorption. We carried out this study to gain knowledge about the current status of FGF-23 levels in our population and its relationship

Endocrine and Paracrine Role of FGF23 and Klotho in Health and Disease

Endocrine and Paracrine Role of FGF23 and Klotho in Health and Disease
  • Author : Reinhold G. Erben,L. Darryl Quarles
  • Publisher : Frontiers Media SA
  • Release : 05 April 2019
GET THIS BOOK Endocrine and Paracrine Role of FGF23 and Klotho in Health and Disease

αKlotho and fibroblast growth factor-23 (FGF23) were discovered independently about 20 years ago. Since their initial description, a series of exciting discoveries have revealed the important role of endocrine and paracrine FGF23 and αKlotho signaling not only for the physiological regulation of mineral and bone homeostasis, but also for the pathophysiology of diseases such as chronic kidney disease, left ventricular hypertrophy, myocardial infarction, hypertension, and disorders characterized by impaired bone mineralization. The 11 articles compiled in this Research Topic consist of three

Fibroblast Growth Factor 23 Induces Left Ventricular Hypertrophy

Fibroblast Growth Factor 23 Induces Left Ventricular Hypertrophy
  • Author : Ansel Philip Amaral
  • Publisher : Unknown
  • Release : 16 June 2021
GET THIS BOOK Fibroblast Growth Factor 23 Induces Left Ventricular Hypertrophy

Over one in ten adults manifests physiological evidence of chronic kidney disease (CKD), which significantly reduces life expectancy due to cardiovascular complications. Left ventricular hypertrophy (LVH) is at the center of this relationship and up to 90% of patients with CKD also manifest LVH. Fibroblast growth factor (FGF) 23 is a phosphorus-regulating hormone responsible for maintaining normal serum phosphate levels in early stages of CKD; furthermore, FGF23 levels rise during the course of the disease and correlate with the CKD stage. High

Fibroblast Growth Factor 23 and Sudden Versus Non sudden Cardiac Death

Fibroblast Growth Factor 23 and Sudden Versus Non sudden Cardiac Death
  • Author : Anonim
  • Publisher : Unknown
  • Release : 16 June 2021
GET THIS BOOK Fibroblast Growth Factor 23 and Sudden Versus Non sudden Cardiac Death

BACKGROUND: Elevated fibroblast growth factor 23 (FGF-23) concentrations are associated with greater risk of cardiovascular events and mortality, especially among people with chronic kidney disease (CKD). Because individuals with CKD are at an increased risk of sudden cardiac death (SCD), we sought to understand whether FGF-23 level is a stronger risk factor for SCD versus non-SCD. STUDY DESIGN: Cohort study. SETTING & PARTICIPANTS: 3,244 participants 65 years or older in the community-based Cardiovascular Health Study. PREDICTOR: Plasma FGF-23 concentrations. OUTCOMES: We assessed SCD and

Endocrine FGFs and Klothos

Endocrine FGFs and Klothos
  • Author : Makoto Kuro-o
  • Publisher : Springer Science & Business Media
  • Release : 06 March 2012
GET THIS BOOK Endocrine FGFs and Klothos

Fibroblast growth factors (FGFs) have been recognized primarily as autocrine/paracrine factors that regulate embryonic development and organogenesis. However, recent studies have revealed that some FGFs function as endocrine factors and regulate various metabolic processes in adulthood. Such FGFs, collectively called endocrine FGFs, are comprised of three members (FGF15/19, FGF21, and FGF23: FGF15 is the mouse ortholog of human FGF19). These endocrine FGFs share a common structural feature that enables the endocrine mode of action at the expense of the

Phosphate and Vitamin D in Chronic Kidney Disease

Phosphate and Vitamin D in Chronic Kidney Disease
  • Author : M.S. Razzaque
  • Publisher : Karger Medical and Scientific Publishers
  • Release : 02 May 2013
GET THIS BOOK Phosphate and Vitamin D in Chronic Kidney Disease

The enormous progress made during the last decade has resulted in a better conceptual understanding of mineral ion metabolism in general. With regard to chronic kidney disease, the two most affected nutrients are phosphate and vitamin D. This book provides an overview of the physiological aspects of phosphate and vitamin D metabolism, and how their pathological dysregulation facilitates advancement of chronic kidney disease. It looks into the complex molecular and organ cross-talks during disease progression that range from the involvement